Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Raltegravir was the first INSTI to be approved for the treatment of HIV infection and has been studied extensively as part of regimens for treatment-experienced patients[Steigbigel 2008]
  • It has been studied as a switch regimen primarily to improve tolerability but is currently less favored than other INSTIs because it is administered twice daily and has a lower barrier to resistance than dolutegravir or bictegravir/emtricitabine/tenofovir AF
  • Studies evaluating switches in suppressed patients receiving stable lopinavir/ritonavir-based antiretroviral therapy switched to raltegravir found improvements in serum lipids

    Action required